If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of NMN varies by jurisdiction and has changed over time. Some countries allow it in dietary supplements, while others treat it as a novel food ingredient requiring safety review. In the United States, the Food and Drug Administration has questioned whether NMN can be lawfully marketed as a dietary supplement because of drug preclusion provisions. Sports organizations have separate rules, and NMN is not currently on the World Anti-Doping Agency prohibited list. These differences create uncertainty for manufacturers, retailers, and researchers seeking consistent legal pathways.
Nicotinamide mononucleotide is usually handled as a dry powder because moisture can promote hydrolysis and shorten shelf life. Recommended storage conditions often include a desiccated container at minus twenty degrees Celsius or colder, with protection from light. Aqueous solutions are less stable than solid material and may degrade faster at ambient temperature or neutral pH. Repeated freeze-thaw cycles can introduce variability, so aliquoting is common in laboratory settings. These practices reflect general nucleotide chemistry rather than a single universal protocol.
Analytical laboratories identify and quantify NMN using several complementary techniques. High-performance liquid chromatography with ultraviolet detection is widely used for purity and assay work. Liquid chromatography coupled to mass spectrometry provides greater sensitivity and is common for biological matrices. Nuclear magnetic resonance spectroscopy supports structural confirmation and can distinguish related nucleotides. Accurate measurement depends on reference standards, validated methods, and careful sample preparation, especially because NMN can convert to related compounds under some conditions.
Quality control for NMN focuses on identity, purity, and the absence of harmful contaminants. Certificates of analysis may report high-performance liquid chromatography purity, mass spectrometry identity, residual solvents, heavy metals, and microbial limits, depending on grade and intended use. Because NMN can exist as different isomers, salts, or hydrates, specification sheets should state the exact form being tested. There is no single globally harmonized purity standard for NMN products. Open questions include which degradation products are most relevant under real-world storage and how analytical results from different laboratories can be compared reliably.
Analytical measurement of NMN typically uses reversed-phase high-performance liquid chromatography with ultraviolet detection near 260 nm. Mass spectrometry, often coupled to liquid chromatography, provides sensitive quantification and confirmatory identification in biological matrices. Nuclear magnetic resonance spectroscopy is used to verify molecular structure and distinguish related nucleotides. Because NMN is polar and poorly retained on conventional reversed-phase columns, ion-pairing reagents or hydrophilic interaction chromatography are sometimes employed. Reported purity values depend on the chosen method, calibration standard, and whether related substances are resolved.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual description can vary by batch and form |
| Typical storage temperature | -20 °C or below | Desiccated, protected from light |
| Common purity method | HPLC-UV | Used for assay and impurity profiling |
| Confirmatory method | LC-MS or NMR | Identity and structural confirmation |
| Regulatory status | Varies by jurisdiction | Not harmonized as supplement or food |
Commercial NMN is produced through enzymatic or chemical routes, and the resulting material can vary in purity, counterion, and residual solvent content. Buyers typically rely on certificates of analysis, but independent verification through third-party laboratories provides stronger assurance. Regulatory treatment differs by country; in the United States, NMN has been subject to shifting guidance about its status as a dietary supplement, while other markets permit sales under local rules. No universal pharmacopeial monograph exists for NMN, so specifications often come from suppliers, research protocols, or regional requirements.
Solid NMN is generally handled as a moisture-sensitive compound. Dry material stored desiccated at low temperature, protected from light, tends to remain stable for extended periods. Aqueous solutions are less stable and can undergo hydrolysis, especially at elevated temperature or alkaline pH. The anomeric form also matters: beta-NMN is the naturally occurring form, while alpha-NMN can appear as a synthetic impurity. Purity and storage conditions therefore influence both analytical results and experimental reproducibility.
Identity and purity are usually assessed with complementary methods. Nuclear magnetic resonance spectroscopy can confirm the molecular structure and distinguish anomeric forms. High-performance liquid chromatography with ultraviolet detection or mass spectrometry is common for assay and related-substance testing. Mass spectrometry also supports trace quantification in biological samples, often with isotope-labeled internal standards. Because NMN lacks a strong chromophore, some ultraviolet methods require careful wavelength selection or derivatization, and laboratories may validate each approach for its intended matrix.
Analytical measurement of NMN typically uses high-performance liquid chromatography with ultraviolet detection, often at a wavelength near 260 nanometers. Liquid chromatography coupled with tandem mass spectrometry provides greater sensitivity and specificity, especially for biological samples. Nuclear magnetic resonance spectroscopy can confirm structure and detect certain impurities. Purity values reported by suppliers depend on the analytical method, calibration standards, and whether related compounds such as nicotinamide or NAD+ are included in the calculation. Independent verification is useful because supplement labels may not fully describe the tested material.
Regulatory treatment of NMN differs by country and has changed over time. In the United States, the Food and Drug Administration has stated that NMN is excluded from the definition of a dietary supplement because it was investigated as a drug before being marketed as a supplement; enforcement and legal interpretation continue to evolve. In the European Union, NMN may require authorization as a novel food before sale. In Japan, NMN has been marketed in some food products, while it is not approved as a therapeutic drug in major markets. These categories affect labeling, permitted claims, and quality oversight.
Solid NMN is generally handled as a moisture-sensitive and light-sensitive material. Suppliers commonly recommend storage at minus 20 degrees Celsius in a sealed, desiccated container, protected from light. Aqueous solutions are less stable than the solid and may degrade faster at elevated temperatures or extreme pH values. Because NMN contains a phosphate ester and a glycosidic bond, hydrolysis and other degradation pathways are plausible under unfavorable conditions. Stability data from independent laboratories remain limited, so handling recommendations often reflect supplier practice rather than published consensus.
Cryptogenic organizing pneumonia (COP), formerly known as bronchiolitis obliterans organizing pneumonia (BOOP), is an inflammation of the bronchioles (bronchiolitis) and surrounding tissue in the lungs. It is a form of idiopathic interstitial pneumonia. It is often a complication of an existing chronic inflammatory disease such as rheumatoid arthritis, dermatomyositis, or it can be a side effect of certain medications such as amiodarone. COP was first described by Gary Epler in 1985. The clinical features and radiological imaging resemble infectious pneumonia. However, diagnosis is suspected after there is no response to multiple antibiotics, and blood and sputum cultures are negative for organisms.
Belgium banned the sale of disposable vapes from 1 January 2025, becoming the first EU member state to do so. In France, parliament voted in February 2025 to ban single-use e-cigarettes, citing environmental impacts alongside public health concerns. In the United Kingdom, a ban on the sale and supply of single-use vapes took effect on 1 June 2025 while permitting the sale of reusable products, and government guidance states that vape sellers must offer a Waste Electrical and Electronic Equipment (WEEE) take-back service for returned vapes and parts. In November 2025, the Irish government approved publication of the Public Health (Single Use Vapes) Bill 2025, intended to prohibit the retail sale of disposable vapes following enactment. In September 2025, a "non-reusable" electronic cigarette was salvaged to demonstrate a web server hosting a website by Bogdan Ionescu.
Nanoparticles, tiny carriers engineered at a molecular level, can protect drugs from being broken down too quickly in the body, improve how well they're absorbed, and deliver them directly to the tissues where they're needed. This targeted delivery not only reduces side effects but also helps patients stay on track with their treatments. These advances in nanotechnology are transforming the landscape of drug delivery and are emphasizing the importance of developing the next generation of CR systems.
== History == In 1988, Stark introduced an "Ethics in Patient Referrals" bill concerning physician self-referrals. Some of the ideas in the bill became law as part of the Omnibus Budget Reconciliation Act of 1990. In specific, what is referred to as "Stark I" prohibited a physician referring a Medicare patient to a clinical laboratory if the physician or his/her family member has a financial interest in that laboratory. It was codified in the United States Code, Title 42, Section 1395nn (42 U.S.C. 1395nn, "Limitation on certain physician referrals"). The Omnibus Budget Reconciliation Act of 1993 contained what is known as "Stark II" amendments to the original law. "Stark II" extended the "Stark I" provisions to Medicaid patients and to DHS other than clinical laboratory services. The Centers for Medicare and Medicaid Services has issued rules in the Federal Register to implement Stark Law, including a 2001 "Phase I" final rule, a 2004 "Phase II" interim final rule, and a 2007 "Phase III" final rule.
DNA templated synthesis of combinatorial libraries described in 2001 by Gartner et al. Dual pharmacophore DNA encoded combinatorial libraries invented in 2004 by Mlecco et al. Sequence encoded routing published by Harbury Halpin and Harbury in 2004. Single pharmacophore DNA encoded combinatorial libraries introduced in 2008 by Manocci et al. DNA encoded combinatorial libraries formed by using yoctoliter-scale reactor published by Hansen et al. in 2009 Details are found about their synthesis and application in the page DNA-encoded chemical library. The DNA encoded soluble combinatorial libraries have drawbacks, too. First of all the advantage coming from the use of solid support is completely lost. In addition, the polyionic character of DNA encoding chains limits the utility of non-aqueous solvents in the synthesis. For this reason many laboratories choose to develop DNA compatible reactions for use in the synthesis of DECLs. Quite a few of available ones are already described
Sources: en.wikipedia.org
In the March 2005 issue of Science, Mary Higby Schweitzer of North Carolina State University and colleagues announced the recovery of soft tissue from the marrow cavity of a fossilized leg bone from a T. rex. The bone had been intentionally, though reluctantly, broken for shipping and then not preserved in the normal manner, specifically because Schweitzer was hoping to test it for soft tissue. Designated as the Museum of the Rockies specimen 1125, or MOR 1125, the dinosaur was previously excavated from the Hell Creek Formation. Flexible, bifurcating blood vessels and fibrous but elastic bone matrix tissue were recognized. In addition, microstructures resembling blood cells were found inside the matrix and vessels. The structures bear resemblance to ostrich blood cells and vessels. Whether an unknown process, distinct from normal fossilization, preserved the material, or the material is original, the researchers do not know, and they are careful not to make any claims about preservation. If it is found to be original material, any surviving proteins may be used as a means of indirectly guessing some of the DNA content of the dinosaurs involved, because each protein is typically created by a specific gene. The absence of previous finds may be the result of people assuming preserved tissue was impossible, therefore not looking. Since the first, two more tyrannosaurs and a hadrosaur have also been found to have such tissue-like structures. Research on some of the tissues involved has suggested that birds are closer relatives to tyrannosaurs than other modern animals.
Willem Vrolik, a Dutch anatomist who was also curator of the "Museum Vrolikianum", which made him privy to many specimens of bodies having birth defects, coined the term "osteogenesis imperfecta" in his bilingual Latin and Dutch language book on teratology, Illustrations of Human and Mammalian Embryogenesis, first published in 1849. Included is a description of the remains of an infant who had what is now known as perinatally fatal OI type II (as verified in a 1998 re-examination of the remains by Baljet et al.). The remains were first given to Vrolik's father, who could not make sense of them. Vrolik described poorly mineralized bones, bowed long bones, and fractures in various states of healing. Vrolik correctly determined that what he termed OI in the infant was not caused by secondary rickets, but a congenital abnormality causing primary osteopenia; he theorized this was due to a lack of "intrinsic generative energy".
=== Interactions with IgG and serum albumin === In addition to binding to IgG, FCGRT has been shown to interact with human serum albumin. FcRn-mediated transcytosis of IgG across epithelial cells is possible because FcRn binds IgG at acidic pH (<6.5) but not at neutral or higher pH. The binding site for FcRn on IgG has been mapped using functional and structural studies, and involves in the interaction of relatively well conserved histidine residues on IgG with acidic residues on FcRn.
=== Drug interactions === Clinical drug-drug interactions with dalbavancin have not been studied, and dalbavancin does not appear to interact with cytochrome P450 substrates, inhibitors, or inducers. It was found to have an in vitro synergistic interaction with the antimicrobial oxacillin, but the clinical significance of this interaction has yet to be established.
A pharmacy (also known as a chemist in Australia, New Zealand and the British Isles; or drugstore in North America; retail pharmacy in industry terminology; or apothecary, historically) is where most pharmacists practice the profession of pharmacy. It is the community pharmacy in which the dichotomy of the profession exists; health professionals who are also retailers. Community pharmacies usually consist of a retail storefront with a dispensary, where medications are stored and dispensed. According to Sharif Kaf al-Ghazal, the opening of the first drugstores are recorded by Muslim pharmacists in Baghdad in 754 AD.
Sources: en.wikipedia.org
The risk information seeking and processing (RISP) model analyzes social implications that affect attitudes and decision making pertaining to clinical trials. People who hold a higher stake or interest in the treatment provided in a clinical trial showed a greater likelihood of seeking information about clinical trials. Cancer patients reported more optimistic attitudes towards clinical trials than the general population. Having a more optimistic outlook on clinical trials also leads to greater likelihood of enrolling.
=== Toffee === Toffee is a free lossless file format for data-independent acquisition mass spectrometry that leverages HDF5 and aims to achieve file sizes similar to those seen in proprietary/vendor-bound formats.
=== Pharmacokinetics === The systemic absorption and toxicity of orally administered selenium sulfide has been studied in animals. Topical use of selenium sulfide in the form of a shampoo or lotion in humans does not appear to normally increase circulating or urinary selenium levels. However, application of selenium disulfide to damaged skin can result in systemic absorption and has been associated with cases of toxicity. Selenium disulfide appears to be much less toxic than other selenium salts, which may be attributed to its low aqueous solubility and very poor systemic absorption.
=== Counseling === Cognitive behavioral therapy (CBT) treatment has been demonstrated as a more effective form of treatment for BED than behavioral weight loss programs. About 50% of individuals with BED achieve complete remission from binge eating and 68-90% will reduce the amount of binge eating episodes they have. CBT has also been shown to be an effective method to address self-image issues and psychiatric comorbidities (e.g., depression) associated with the disorder. The goal of CBT is to interrupt binge-eating behavior, learn to create a normal eating schedule, change the perception around weight and shape, and develop positive attitudes about one's body. While CBT has been effective in eliminating BED, it most of the time does not result in a person losing weight. Recent reviews have concluded that psychological interventions such as psychotherapy and behavioral interventions are more effective than pharmacological interventions for the treatment of binge eating disorder. A meta-analysis concluded that psychotherapy based on CBT not only significantly improved binge-eating symptomatology but also reduced a client's BMI significantly at posttreatment and longer than 6 and 12 months after treatment. Behavioral weight loss treatment has been proven to be effective as a means to achieve weight loss amongst patients with BED.
Sources: en.wikipedia.org
Solid NMN is often kept cool, dry, and protected from light. Long-term storage may use temperatures at or below minus twenty degrees Celsius. Moisture and repeated temperature changes should be avoided.
Common methods include HPLC with ultraviolet detection, LC-MS, and NMR. HPLC is often used for purity, while LC-MS offers sensitivity in complex samples. NMR helps confirm chemical identity.
Countries classify ingredients according to their own food, supplement, and drug laws. NMN may be treated as a supplement, a novel food, or a substance linked to drug review. As a result, legal status can change and is not harmonized internationally.
Liquid chromatography coupled with tandem mass spectrometry is widely used because it can separate NMN from related nucleotides and quantify low concentrations. Stable isotope-labeled internal standards help correct for matrix effects and recovery losses. Ultraviolet detection alone is less specific for complex biological matrices.